SenoRx Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SenoSonix System, an integration of its EnCor breast biopsy system with a state-of-the-art ultrasound Imaging system, incorporating SenoRx's EnCor vacuum-assisted biopsy technologies with an ultrasound system developed and sold by Ultrasonix Medical Corporation of Canada.
SenoRx and Ultrasonix have enjoyed a close working relationship, jointly developing the technology that facilitates the integration of the two products. The product will be branded SenoSonix and marketed as SenoSonix with EnCor Inside.